GT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.68 USD | -5.64% |
|
+17.95% | -51.90% |
| 05-21 | Top Midday Decliners | MT |
| 05-21 | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 32.65 | 5.462 | 35.83 | 93.05 | 28.84 | 10.56 |
| Enterprise Value (EV) 1 | 43.39 | 18.79 | 56.87 | 61.1 | 12.5 | -3.352 |
| P/E ratio | -0.13 x | -0.12 x | -1.12 x | -1.48 x | -1.35 x | -1.36 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -2.01 x | -1.64 x | -8.41 x | - | - | - |
| EV / FCF | 55.4 x | 80.5 x | -16.6 x | 7.47 x | -1.15 x | 0.71 x |
| FCF Yield | 1.81% | 1.24% | -6.02% | 13.4% | -87.3% | 140% |
| Price to Book | 2.85 x | -0.3 x | -1.29 x | 4.46 x | 2.47 x | 1.41 x |
| Nbr of stocks (in thousands) | 98.5 | 132 | 166 | 1,017 | 1,085 | 1,381 |
| Reference price 2 | 331.5 | 41.31 | 216.2 | 91.50 | 26.57 | 7.650 |
| Announcement Date | 19-03-29 | 20-03-27 | 21-04-16 | 22-03-28 | 23-03-30 | 24-03-26 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -21.55 | -11.45 | -6.76 | - | - | - |
| EBIT 1 | -21.55 | -11.46 | -6.764 | -57.52 | -21.26 | -13.58 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -259.2 | -38.65 | -28.3 | -58.01 | -20.88 | -7.597 |
| Net income 1 | -259.2 | -38.65 | -28.3 | -58.01 | -20.88 | -7.597 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -2,631 | -342.6 | -193.6 | -61.81 | -19.66 | -5.637 |
| Free Cash Flow 1 | 0.7836 | 0.2334 | -3.422 | 8.175 | -10.91 | -4.701 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-03-29 | 20-03-27 | 21-04-16 | 22-03-28 | 23-03-30 | 24-03-26 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -18.18 | -5.442 | -3.014 | -7.023 | -5.778 | -3.665 | -3.621 | -3.122 | -3.168 | -3.091 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -2.266 |
| Net income 1 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -2.266 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -15.60 | -5.100 | -3.000 | -6.600 | -5.400 | -0.3000 | -1.500 | -1.800 | -5.520 | -1.640 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-03-28 | 22-05-16 | 22-08-15 | 22-10-31 | 23-03-30 | 23-05-15 | 23-08-07 | 23-11-01 | 24-03-26 | 24-05-15 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 10.7 | 13.3 | 21 | - | - | - |
| Net Cash position 1 | - | - | - | 31.9 | 16.3 | 13.9 |
| Leverage (Debt/EBITDA) | -0.4986 x | -1.164 x | -3.112 x | - | - | - |
| Free Cash Flow 1 | 0.78 | 0.23 | -3.42 | 8.18 | -10.9 | -4.7 |
| ROE (net income / shareholders' equity) | -197% | 973% | 116% | 1,542% | -124% | -79.1% |
| ROA (Net income/ Total Assets) | -9.63% | -55.5% | -140% | -190% | -54.3% | -55% |
| Assets 1 | 2,691 | 69.61 | 20.27 | 30.53 | 38.44 | 13.81 |
| Book Value Per Share 2 | 116.0 | -140.0 | -168.0 | 20.50 | 10.80 | 5.410 |
| Cash Flow per Share 2 | 0.6000 | 0.2000 | 30.50 | 8.390 | 5.200 | 0.7800 |
| Capex 1 | 0.04 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 19-03-29 | 20-03-27 | 21-04-16 | 22-03-28 | 23-03-30 | 24-03-26 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -51.90% | 7.94M | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- GTBP Stock
- Financials GT Biopharma, Inc.
